Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dice Therapeutics Inc (NQ: DICE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dice Therapeutics Inc

< Previous 1 2 3 4 Next >
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
Via Investor Brand Network
Exposures Product Safety
Why These 3 Large Caps Are Bucking the August Slump
The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023. 
Via MarketBeat
Topics Economy Stocks
Exposures Fossil Fuels Interest Rates US Equities
What 9 Analyst Ratings Have To Say About DICE Therapeutics
Via Benzinga
Analyst Expectations for DICE Therapeutics's Future
Via Benzinga
Health Care Company Eli Lilly Announces Acquisition of DICE Therapeutics
Via Benzinga
Top 5 Health Care Stocks That May Crash In Q3
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Eli Lilly To Report Q2 Earnings: What's In The Cards?
Eli Lilly & Company will report second-quarter 2023 results on Aug. 8, before the market opens. 
Via Talk Markets
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for... 
Via Benzinga
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
From Kahn Swick & Foti, LLC
Via Business Wire
Why Shares of Ventyx Biosciences Rose Monday
The company has several promising autoimmune therapies. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
Via Benzinga
Stock Market Pulls Back After Several Weeks Of Gains: Weekly Review
But the major indexes and leading stocks generally showed healthy action. 
Via Investor's Business Daily
Why Dice Therapeutics Stock Bolted Higher This Week
The small-cap drugmaker fetched a hefty premium in a buyout deal with Eli Lilly. 
Via The Motley Fool
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?
The pharma giant's latest acquisition might be on the small side, but it could yield an important new growth driver in the years ahead. 
Via The Motley Fool
DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2023
Via Benzinga
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer. 
Via MarketBeat
Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know
Lilly could get a couple of promising autoimmune-disease drugs with the transaction. 
Via The Motley Fool
Crude Oil Down 2%; Dragonfly Energy Shares Plunge
U.S. stocks traded lower toward the end of trading, with Dow Jones dropping over 150 points on Tuesday. The Dow traded down 0.50% to 34,129.29while the NASDAQ fell 0.16% to 13,668.76 The S&P 500, also... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Dips Over 300 Points; DICE Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with Dow Jones dropping over 300 points on Tuesday. The Dow traded down 0.96% to 33,969.42 while the NASDAQ fell 0.74% to 13,588.13. The S&P 500, also... 
Via Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. 
Via Benzinga
Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments
Via Spotlight Growth
Why Shares of Dice Therapeutics Are Skyrocketing Tuesday
The company received a buyout offer from Eli Lilly. 
Via The Motley Fool
PLTR Stock Alert: Why Raymond James Just Downgraded Palantir
Palantir (PLTR) stock is on the move Tuesday after Raymond James analysts downgraded the company's shares but increased its price target. 
Via InvestorPlace
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
RIVN Stock Alert: Rivian Jumps on the Tesla Bandwagon for EV Charging
Rivian (RIVN) stock is in the news Tuesday as investors react to the electric vehicle (EV) company joining Tesla's (TSLA) charging standard. 
Via InvestorPlace
US Stocks Mixed; Housing Starts Surge In May
U.S. stocks traded mixed this morning, with Dow Jones dropping over 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.52% to 34,120.19 while the NASDAQ rose 0.15% to... 
Via Benzinga
Eli Lilly To Acquire Small Company DICE Therapeutics Focused On Autoimmune Diseases For $2B
Eli Lilly And Co (NYSE: LLY) has agreed to acquire DICE Therapeutics Inc (NASDAQ: DICE), a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop oral... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.